Quality Investor

CTS Corporation

Rank #255Capital Return

CTS · NYSE · Technology

CTS Corporation (CTS) — Rank #255 by gross profitability (GP/assets 0.27) · ROE 11.7% · Piotroski F-Score N/A.

As-of 2026-09-15 · CIK 0000026058 · all metrics point-in-time as of the filing date.

About

CTS Corporation designs, manufactures, and sells sensors, connectivity components, and actuators in North America, Europe, and Asia.

Show more

The company offers controls, pedals, sensors, switches, transducers, and piezo sensing products; EMI/RFI filters, capacitors, resistors, RF filters, and frequency control products; and piezo microactuators and rotary actuators. It serves transportation, industrial, medical, aerospace, and defense industries. The company sells and markets its products through its sales engineers, independent manufacturer representatives, and distributors.

CTS Corporation was founded in 1896 and is headquartered in Lisle, Illinois.

Industry
Electronic Components
Sector
Technology
State
IN
Filer Category
Large accelerated filer
Fiscal Year End
December 31

Price History

CTS+71.8% · +11.4% CAGRSPY+80.5% · +12.5% CAGR

Company Snapshot

P/E and reverse DCF are the primary valuation lenses at this stage.

Market Cap

$1.61B

P/E (annual)

25.8

P/S (annual)

3.0

P/B

2.9

P/OCF (annual)

15.8

Shareholder Yield

3.3%

Employees

Industry

Electronic Components

Exchange

NYSE

Signal Flags

4 green
Revenue growth acceleratingGrowth rate increasing year over year
Operating leverage expandingOperating income growing faster than revenue
Deferred revenue growingRevenue and deferred revenue both growing — retention signal
Sequential beat (rev + EPS)Both revenue and EPS exceeded prior quarter — 1-quarter streak

Quality Profile

Profitability

1/1 pass
GP / assets
0.27
Return on equity
11.7%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.39
Current ratio
2.52×
Net cash
$90.85M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue

Growth

2/2 pass
Revenue growth
5.2%
Piotroski F-Score
N/A
Share dilution
-3.0%

Terry Smith quality gate

Passes 1/5 Terry Smith thresholds

1 of 5 threshold not computable from filed data.

What Growth Is Priced In

Implied revenue growth (10Y)

7.4%

incredible deal

The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).

Buyback tailwind: -3.0% — per-share value needs a total required return of 4.4% once share-count change is priced in.

vs. own 6-year median revenue growth: -0.5%

Cost-of-equity sensitivity (implied growth at different discount rates)

r = 8%

3.1%

r = 10% (base)

7.4%

r = 12%

11.1%

Net debt / market cap: -5.4%

Base FCF: $86.4M3Y mean FCF: $80.4M

Valuation History

Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.

P / E

Price / diluted EPS

24.2xFair
22.8xmed 24.2x73.6x

P / S

Price / revenue per share

2.9xExpensive
2.1xmed 2.5x2.9x

P / B

Price / book value per share

2.9xExpensive
2.4xmed 2.7x3.3x

P / GP

Price / gross profit per share

7.6xExpensive
6.2xmed 7.3x7.6x

P / FCF

Price / free cash flow per share

18.3xFair
13.1xmed 18.7x39.4x

FCF yield, shareholder yield, and buyback activity are the primary reads at this stage.

Profitability

Gross profitability (GP / assets)

0.27

Primary signal (Novy-Marx).

45th pctl of 43 SIC 36 peers

Return on equity

11.7%

Gross margin

38.4%

26th pctl of 43 SIC 36 peers

Revenue growth (YoY)

5.2%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

-2.7%

Revenue CAGR (5Y)

5.0%

Earnings CAGR (3Y)

3.1%

FCF CAGR (3Y)

-6.8%

Anti-fragile safety

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.39

62nd pctl of 41 SIC 36 peers (best = lowest)

Current ratio

2.52×

45th pctl of 43 SIC 36 peers

Quick ratio

1.75×

Net cash

$90.85M

Cash & equivalents minus total debt.

Cash-flow health

Free cash flow

$86.37M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF / net income

0.32

Cash-backing of earnings.

FCF/NI divergence

Unfavorable divergence (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

Stock-based comp intensity.

Dividend safety

Composite score

3.0 / 5

Good
Payout ratio
7.3%5/5 Strong
FCF coverage
18.18×5/5 Strong
Dividend growth streak
0 yr0/5 Weak
Balance-sheet health
D/E 0.39 · IC N/A2/5 Fair

Piotroski F-Score

F-Score

N/A

Only 8/9 components determinable.

Lifecycle Phase History

20202025
Decline
Hypergrowth
Capital Return
Value